ADVANCING THERAPIES TO TRANSFORM THE TREATMENT OF inflammatory and immunologic diseases
RAPT Therapeutics is focused on the development of therapies for patients with significant unmet needs in inflammatory and immunologic diseases. Utilizing our deep and proprietary expertise in immunology, we are developing novel molecules that are designed to modulate the critical immune responses underlying these diseases.
A PIPELINE INTENT ON IMPROVING COUNTLESS LIVES
*RAPT owns ex-China rights including US, Europe, and Japan; Jemincare owns rights in China, Taiwan, Hong Kong and Macau
†Regional collaboration and license with Hanmi in Korea, Taiwan and China (including Hong Kong and Macau). We are seeking a partner to further develop tivumecirnon outside the Hanmi Territory.